Welcome to

KaNDy
Therapeutics

Developing a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening

FIND OUT MORE

A unique approach

Progressing our unique once daily dual mechanism neurokinin antagonist, NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. NT-814 has successfully completed a Phase 2a proof of concept study that demonstrated its potential to rapidly and profoundly reduce two key symptoms of the menopause: hot flashes and night time awakening. Preparations are underway for a multi-country Phase 2b study with NT-814 in this anchor Women’s Health indication, starting in Q4 2018.

Latest News

By
In Company News
Posted

Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College London has joined KaNDy Therapeutics as a Scientific and Clinical Advisor.

Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College [...]

READ MORE

Contact Us

For general, media or partnership enquiries, get in touch with us:

Contact Us
Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt